Previously, we proposed a gene therapy strategy for DM1 that involved MBNL overexpression, leading to an increase in the nonsequestered nuclear pool of MBNL protein and reversal of DM1-associated RNA missplicing and pathology. Here, MBNL1 is linked to myotonic dystrophy type 1.